.Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA14_Heparin.Heparin .Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA14_Heparin.Heparin| name: | Heparin |
| ATC code: | S01XA14 | route: | intravenous |
| n-compartments | 2 |
Heparin is an anticoagulant drug used to prevent and treat blood clots in conditions such as deep vein thrombosis, pulmonary embolism, and during surgeries. It is a naturally occurring glycosaminoglycan and is usually administered intravenously or subcutaneously. Heparin is still widely used and is approved for these indications.
Pharmacokinetic parameters represent typical values in healthy adult individuals after intravenous bolus administration.
Izadpanah, M, et al., & Mohammadi, M (2015). Heparin and related drugs for venous thromboembolism prophylaxis: subcutaneous or intravenous continuous infusion?. Journal of comparative effectiveness research 4(2) 167–184. DOI:10.2217/cer.14.78 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25825845
Moffett, BS, et al., & Yee, DL (2017). Population pharmacokinetics of human antithrombin concentrate in paediatric patients. British journal of clinical pharmacology 83(11) 2450–2457. DOI:10.1111/bcp.13359 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28664670
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969